Evidence map›Paper›PMID 39300281›Full record

ArticleCommunications biology2024

Whole brain modelling for simulating pharmacological interventions on patients with disorders of consciousness.

I Mindlin, R Herzog, L Belloli, D Manasova, M Monge-Asensio, J Vohryzek, A Escrichs, N Alnagger, P Núñez, O Gosseries and 7 more

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

I MindlinInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France. ivan.mindlin@icm-institute.org.ORCID 0000-0001-6041-6081
R HerzogInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France.ORCID 0000-0002-3498-5819
L BelloliInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France.
D ManasovaInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France.
M Monge-AsensioCenter for Brain and Cognition, Computational Neuroscience Group, Universitat Pompeu Fabra, Barcelona, Spain.
J VohryzekCenter for Brain and Cognition, Computational Neuroscience Group, Universitat Pompeu Fabra, Barcelona, Spain.
A EscrichsCenter for Brain and Cognition, Computational Neuroscience Group, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-6482-9737
N AlnaggerComa Science Group, GIGA Consciousness, University of Liège, Liège, Belgium.
P NúñezComa Science Group, GIGA Consciousness, University of Liège, Liège, Belgium.
O GosseriesComa Science Group, GIGA Consciousness, University of Liège, Liège, Belgium.ORCID 0000-0001-9011-7496
M L KringelbachCentre for Eudaimonia and Human Flourishing, Linacre College, University of Oxford, Oxford, UK.ORCID 0000-0002-3908-6898
G DecoCenter for Brain and Cognition, Computational Neuroscience Group, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-8995-7583
E TagliazucchiConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ministry of Science, Technology and Innovation, Buenos Aires, Argentina.
L NaccacheInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France.ORCID 0000-0002-2874-1009
B RohautInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France.
J D SittInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France. jacobo.sitt@icm-institute.org.ORCID 0000-0002-3878-4846
Y Sanz PerlInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, 75013, France. yonatan.sanz@upf.edu.ORCID 0000-0002-1270-5564

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disorders of consciousness (DoC) represent a challenging and complex group of neurological conditions characterised by profound disturbances in consciousness. The current range of treatments for DoC is limited. This has sparked growing interest in developing new treatments, including the use of psychedelic drugs. Nevertheless, clinical investigations and the mechanisms behind them are methodologically and ethically constrained. To tackle these limitations, we combined biologically plausible whole-brain models with deep learning techniques to characterise the low-dimensional space of DoC patients. We investigated the effects of model pharmacological interventions by including the whole-brain dynamical consequences of the enhanced neuromodulatory level of different neurotransmitters, and providing geometrical interpretation in the low-dimensional space. Our findings show that serotonergic and opioid receptors effectively shifted the DoC models towards a dynamical behaviour associated with a healthier state, and that these improvements correlated with the mean density of the activated receptors throughout the brain. These findings mark an important step towards the development of treatments not only for DoC but also for a broader spectrum of brain diseases. Our method offers a promising avenue for exploring the therapeutic potential of pharmacological interventions within the ethical and methodological confines of clinical research.

Indexed as

BrainConsciousness DisordersDeep LearningHumansMaleModels, Neurological

Identifiers

PMID39300281
PMCPMC11413186

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.